Recent Finacing
Recent Raise
Sirnaomics discovers and develops RNAi therapeutics, advancing dual‑targeting siRNAs (STP705/STP707) and systemic delivery platforms (GalNAc, siRNA‑chemodrug, nanoparticle) for cancer, fibrosis, viral, and metabolic indications.
